We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

150 hedge funds and large institutions have $1.73B invested in Ventyx Biosciences in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 70 increasing their positions, 30 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 30

16% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 25

4.44% more ownership

Funds ownership: 85.47%89.91% (+4.4%)

3% more funds holding

Funds holding: 146150 (+4)

4% more capital invested

Capital invested by funds: $1.67B → $1.73B (+$59.7M)

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

77% less call options, than puts

Call options by funds: $7.2M | Put options by funds: $31.6M

Holders
150
Holders Change
+4
Holders Change %
+2.74%
% of All Funds
2.36%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.05%
New
29
Increased
70
Reduced
30
Closed
25
Calls
$7.2M
Puts
$31.6M
Net Calls
-$24.4M
Net Calls Change
-$30.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Wells Fargo
76
Wells Fargo
California
$1.22M +$772K +22,398 +152%
CS
77
Credit Suisse
Switzerland
$1.21M +$786K +22,798 +162%
Legal & General Group
78
Legal & General Group
United Kingdom
$1.21M +$905K +26,254 +248%
MAP
79
Moody Aldrich Partners
Massachusetts
$1.2M -$1.83K -53 -0.1%
MB
80
MPM BioImpact
Massachusetts
$1.04M +$1.09M +31,747 New
Brown Advisory
81
Brown Advisory
Maryland
$1.03M +$1.08M +31,406 New
Tudor Investment Corp
82
Tudor Investment Corp
Connecticut
$959K +$168K +4,888 +20%
Connor, Clark & Lunn Investment Management (CC&L)
83
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$876K +$921K +26,704 New
BC
84
Birchview Capital
Vermont
$866K
Invesco
85
Invesco
Georgia
$858K +$418K +12,126 +86%
SCM
86
Silverarc Capital Management
Massachusetts
$820K -$1.55M -45,000 -64%
MIM
87
MetLife Investment Management
New Jersey
$815K +$407K +11,815 +91%
Janney Montgomery Scott
88
Janney Montgomery Scott
Pennsylvania
$808K +$403K +11,679 +90%
BG
89
Bellevue Group
Switzerland
$804K -$34.5K -1,000 -4%
DC
90
Diametric Capital
Massachusetts
$791K +$294K +8,531 +55%
Barclays
91
Barclays
United Kingdom
$769K +$205K +5,954 +34%
Mirae Asset Global Investments
92
Mirae Asset Global Investments
South Korea
$740K +$336K +9,751 +76%
AIG
93
American International Group
New York
$739K +$362K +10,491 +87%
HF
94
HRT Financial
New York
$734K +$772K +22,397 New
Macquarie Group
95
Macquarie Group
Australia
$724K +$761K +22,081 New
SCM
96
Soleus Capital Management
Connecticut
$699K +$734K +21,300 New
SG Americas Securities
97
SG Americas Securities
New York
$640K +$544K +15,774 +422%
CC
98
Callan Capital
California
$629K
QT
99
Quantbot Technologies
New York
$627K +$573K +16,637 +668%
UBS AM
100
UBS AM
Illinois
$616K

VTYX Hedge Fund Activity: Q2 2023 in Review

150 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q2 2023, worth a combined $1.73B — up 3.6% from $1.67B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new VTYX positions and 25 closed out — a net gain of 4 holders — while 70 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $43.6M. The largest seller was venBio Partners, cutting an estimated $64.6M.

  • 150 institutional investors held Ventyx Biosciences (VTYX) as of Q2 2023, up from 146 in Q1 2023.
  • Funds reported $1.73B of Ventyx Biosciences stock for Q2 2023, up 3.6% quarter-over-quarter.
  • 29 funds opened new Ventyx Biosciences positions in Q2 2023 and 25 closed out, a net change of +4 holders.
  • The largest Ventyx Biosciences buyer in Q2 2023 was T. Rowe Price Associates, an estimated $43.6M added.
  • The largest Ventyx Biosciences seller in Q2 2023 was venBio Partners, an estimated $64.6M sold.

Based on aggregated 13F filings for Q2 2023.